Pharmacologic approaches to cognitive deficits in Alzheimer's disease

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 9, 1998, Pages 22-27

  Peskind, Elaine R ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Education   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; HEPTYLSTIGMINE TARTRATE; METRIFONATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TACRINE;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME INHIBITION; ESTROGEN THERAPY; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

ALZHEIMER DISEASE; ANTIOXIDANTS; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; COGNITION DISORDERS; ESTROGEN REPLACEMENT THERAPY; HUMANS; INDANS; NOOTROPIC AGENTS; PIPERIDINES; PLACEBOS; TACRINE; TREATMENT OUTCOME; TRICHLORFON;

EID: 0031828775     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403-1405
2. Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-126
3. Davis KL, Thai LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327:1253-1259
4. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991
5. Rogers SL, Doody R, Mohs R, et al. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30-week phase III trial [abstract]. Neurology 1996;46:A217
6. Becker RE, Colliver JA, Eible R, et al. Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer disease: report of an open trial. Drug Dev Res 1990;19:425-434
7. Becker RE, Colliver JA, Markwell SJ, et al. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alzheimer Dis Assoc Disord 1996;10:124-131
8. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-1222
9. Kawas C, Resnick S, Morrison A, et al. A retrospective of estrogen replacement therapy and the risk of developing Alzheimer's disease. Neurology 1997;48:1517-1521
10. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996;47:425-432
11. Henderson VW, Paganini-Hill A, Emanuel CK, et al. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and non-demented control subjects. Arch Neurol 1994;51:896-900
12. Drachman DA. Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 1977;27:783-790
13. Sunderland T, Tariot PN, Cohen RM. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. Arch Gen Psychiatry 1987;44:418-426
14. Huff FJ, Mickel SF, Corkin S, et al. Cognitive functions affected by scopolamine in Alzheimer's disease and normal aging. Drug Dev Res 1988;12: 271-278
15. Davis KL, Mohs RC. Enhancement of memory process in Alzheimer's disease with multiple dose intravenous physostigmine. Am J Psychiatry 1982; 139:1421-1424
16. Thai LJ, Masur DM, Blan AD, et al. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease. J Am Geriatr Soc 1989; 37:42-48
17. Soncrant TT, Raffaele KC, Asthana S, et al. Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease. Psychopharmacology (Berl) 1993;112:421-427
18. Jann MW. Preclinical pharmacology of metrifonate. Pharmacotherapy 1998;18(2, pt 2):555-679
19. Summers WK, Viesselman JO, Marsh GM, et al. Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. Biol Psychiatry 1981;16:145-153
20. Rosen WL, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364
21. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-2529
22. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Tacrine Study Group. Neurology 1996;47:166-177
23. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a multicentre, randomized, double-blind placebo-controlled trial. Dementia 1996;7:293-303
24. Schmidt BH, Hinz VC, Blokland A, et al. Preclinical pharmacology of metrifonate: a promise for Alzheimer therapy. In: Becker RE, Giacobini E, Robert P, eds. Alzheimer Disease: From Molecular Biology to Therapy. Boston, Mass: Birkhauser; 1996:217-221
25. Pettigrew LC, Bieber F, Lettieri J, et al. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease. J Clin Pharmacol 1998;38:236-245
26. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-1230
27. Cummings JL, Cyrus PA, Bieber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998;50:1214-1221
28. Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias of Late Life. Am J Psychiatry 1997;154(5 suppl)
29. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465-473
30. Goodman Y, Mattson MP. Secreted forms of beta amyloid precursor protein protect hippocampal neurons against amyloid beta peptide induced oxidative injury. Exp Neurol 1994;128:1-12
31. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371
32. Tariot PN, Cohen RM, Sunderland T, et al. L-Deprenyl in Alzheimer's disease. Arch Gen Psychiatry 1987;44:427-433
33. Burke WJ, Roccaforte WH, Wengel SP, et al. L-Deprenyl in the treatment of mild dementia of the Alzheimer's type: results of a 15-month trial. J Am Geriatr Soc 1993;41:1219-1225
34. Aisen PS, Davis KL. Anti-inflammatory therapy for Alzheimer's disease: a status report. Int J Geriatr Psychopharmacol 1997;1:2-5
35. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-1611
36. Thai LJ. Development of the Alzheimer's Disease Cooperative Study. Int J Geriatr Psychopharmacol 1997;1:6-9
37. Sapolsky RM, Krey LC, McEwen BS. Prolonged glucocorticoid exposure reduces hippocampal neuron numbers: implications for aging. J Neurosci 1985;5:1221-1226
38. Goodman Y, Bruce AJ, Cheng B, et al. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurons. J Neurochem 1996;66:1836-1844
39. Green PS, Gridley KE, Simpkins JW. Estradiol protects against β-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett 1996;218:165-168
40. Fillit H, Weinreb H, Cholst I, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 1986;11:337-345
41. Honjo H, Ogino Y, Naitoh K, et al. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem 1989;34:521-525
42. Asthana S, Craft S, Baker L, et al. Transdermal estrogen improves memory in women with Alzheimer's disease. Soc Neurosci Abstracts 1996;22:83
43. Bergkvist L, Persson I. Hormone replacement therapy and breast cancer: a review of current knowledge. Drug Saf 1996;15:360-370
44. Lobo RA. Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 1995;173(3 pt 2):982-989
45. Oyama Y, Chikahisa L, Ueha T, et al. Ginkgo biloba extract protects brain neurons against oxidative stress induced by hydrogen peroxide. Brain Res 1995;712:349-352
46. Le Bars PL, Katz MM, Berman N, et al, and the North American EGb Study Group. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997;278:1327-1332